26 completed, 4 unknown, 1 active not recruiting. 31 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 31 | Completed 26, Unknown 4, Active not recruiting 1 |
Follow Encephalitis, Arbovirus: new trials by email Literature Review of Encephalitis, Arbovirus trials Research Report on Encephalitis, Arbovirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas Liaoning Chengda Inactivated Japanese Encephalitis Vaccine - Japanese Encephalitis | Phase 4 | Active not recruiting | Liaoning Chengda Biotechnology CO., LTD | 250 | 2024-11-14 | 2024-12-13 |
| Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) Vero cell-drived inactive Japanese encephalitis vaccine, Measles-Mumps-Rubella Vaccine - Japanese Encephalitis, Measles | Phase 4 | Completed | Liaoning Chengda Biotechnology CO., LTD | 408 | 2024-03-02 | 2025-08-28 |
| Primary TBE Vaccination for the Elderly FSME-IMMUN Vaccine - Tick-borne Encephalitis, Vaccine | Phase 4 | Unknown | Region Örebro County | 90 | 2024-01-01 | 2023-11-18 |
| Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province Japanese Encephalitis Vaccine (Vero Cell), Inactivated;, No prospective interventions - Japanese Encephalitis, Vaccine Preventable Disease | Phase 4 | Unknown | Zhejiang Provincial Center for Disease Control and Prevention | 712 | 2021-03-01 | 2022-11-15 |
| Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Live attenuated SA 14-14-2 Japanese Encephalitis vaccine, Measles, mumps, rubella vaccine - Encephalitis, Japanese, Measles | Phase 4 | Completed | PATH | 628 | 2016-10-13 | 2020-10-14 |
| Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Measles-Rubella combined vaccine(MR), Japanese Encephalitis alive vaccine(JE) - Measles, Rubella | Phase 4 | Completed | Centers for Disease Control and Prevention, China | 1043 | 2015-08-01 | 2016-08-01 |
| Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj Japanese encephalitis vaccine - Japanese Encephalitis | Phase 4 | Completed | Boryung Pharmaceutical Co., Ltd | 94 | 2015-08-01 | 2017-02-06 |
| Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine - Encephalitis, Japanese | Phase 4 | Completed | PATH | 561 | 2015-07-30 | 2020-10-19 |
| Application of a TBE-Vaccine in Obese Persons FSME-IMMUN Vaccine - Tick Borne Encephalitis | Phase 4 | Unknown | Medical University of Vienna | 73 | 2015-04-15 | 2019-09-10 |
| Post-licensure Safety Study of IMOJEV® in Thailand IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine - Japanese Encephalitis | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 10000 | 2013-11-01 | 2016-05-04 |
| Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Japanese encephalitis chimeric vaccine (JECV) - Japanese Encephalitis | Phase 4 | Unknown | Khon Kaen University | 88 | 2013-10-01 | 2013-10-08 |
| Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine, Live Attenuated Varicella Vaccine, live attenuated JE vaccine - Japanese Encephalitis, Chickenpox | Phase 4 | Completed | Changchun Keygen Biological Products Co., Ltd. | 497 | 2013-03-01 | 2014-02-24 |
| Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac TicoVac - Tick-Borne Encephalitis | Phase 4 | Completed | University of Surrey | 40 | 2012-10-01 | 2018-08-03 |
| A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 Live attenuated Japanese encephalitis vaccine SA14-14-2 - Japanese Encephalitis, Japanese Encephalitis Vaccine | Phase 4 | Completed | Indian Institute of Science | 17 | 2012-05-01 | 2019-04-26 |
| Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Vaccine produced in existing facility, Vaccine produced in new facility - Japanese Encephalitis | Phase 4 | Completed | PATH | 818 | 2012-05-01 | 2018-12-05 |
| TBE Seropersistence up to 10 Years After First Booster in Adults FSME-IMMUN 0.5 ml - Tick-borne Encephalitis (TBE) | Phase 4 | Completed | Pfizer | 243 | 2012-04-01 | 2021-01-22 |
| Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Blood draw - Tick Borne Encephalitis, Virus Diseases | Phase 4 | Completed | GlaxoSmithKline | 206 | 2012-03-08 | 2021-08-12 |
| This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population IXIARO® - Japanese Encephalitis | Phase 4 | Completed | Valneva Austria GmbH | 200 | 2010-06-01 | 2012-03-23 |
| An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE Serology blood draw - Tick Borne Encephalitis (TBE) | Phase 4 | Completed | Novartis Vaccines | 126 | 2009-05-01 | 2011-12-08 |
| Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401) FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL) - Encephalitis, Tick-Borne | Phase 4 | Completed | Pfizer | 179 | 2009-04-26 | 2018-12-17 |
Showing 20 of 31. Sign in to see all of them.
Encephalitis, Tick-Borne (16) · Encephalitis, Japanese (15) · Measles (3) · Rubella (3) · Mumps (2) · Chickenpox (1) · Flavivirus Infections (1) · Vaccine-Preventable Diseases (1) · Virus Diseases (1)
Arbovirus Infections (31) · Brain Diseases (31) · Central Nervous System Diseases (31) · Central Nervous System Infections (31) · Central Nervous System Viral Diseases (31) · Encephalitis (31) · Encephalitis, Viral (31) · Flaviviridae Infections (31) · Infections (31) · Infectious Encephalitis (31) · Nervous System Diseases (31) · Neuroinflammatory Diseases (31) · RNA Virus Infections (31) · Vector Borne Diseases (31)
Vaccines (3) · Blood Specimen Collection (2) · FSME-IMMUN vaccine (2) · Japanese Encephalitis Vaccines (2) · Measles-Mumps-Rubella Vaccine (2) · Influenza Vaccines (1)
Pfizer (7) · PATH (5) · Novartis (3) · Liaoning Chengda Biotechnology CO., LTD (2) · Medical University of Vienna (2) · Boryung Pharmaceutical Co., Ltd (1) · Centers for Disease Control and Prevention, China (1) · Changchun Keygen Biological Products Co., Ltd. (1) · GlaxoSmithKline (1) · Indian Institute of Science (1) · Khon Kaen University (1) · Novartis Vaccines (1) · Region Örebro County (1) · Sanofi Pasteur, a Sanofi Company (1) · University of Surrey (1)
Germany (7) · Austria (5) · China (5) · Poland (5) · Belgium (2) · Sri Lanka (2) · Thailand (2) · Bangladesh (1) · Czechia (1) · India (1) · Philippines (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
Nihal Abeysinghe, MD, MSc (2) · Ryszard Konior, MD (2) · Ursula Wiedermann-Schmidt, MD, PhD (2) · David JM Lewis (1) · Dr V Ravi, MBBS MD (1) · HJ Jung, MD (1) · Huanyu Wang (1) · Huaqing Wang, MD, PhD (1) · K Zaman, MD (1)
PMID 21592984, PMID 28545923, PMID 25239483, PMID 25728316, PMID 27903416, PMID 28135273, PMID 29429815, PMID 30833160, PMID 30928173, PMID 32528467, PMID 35243320
2009 (1)